Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from Zidovudine- containing backbone to Truvada in HIV-1-infected patients on highly active antiretroviral therapy

Next Previous
X
Search
Trial Profile

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from Zidovudine- containing backbone to Truvada in HIV-1-infected patients on highly active antiretroviral therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine; Zidovudine
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms RECOMB
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 08 Mar 2012 Results assessing the effects of treatment on the fat mass ratio presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 22 Jul 2009 Long-term, 72-week results have been presented at IAS 2009.
    • 10 Feb 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top